Continued Level of Significant Insider Selling at Avexis (AVXS)

Monday, March 05, 2018 10:15 PM ET

Continued Level of Significant Insider Selling at Avexis (AVXS)

A filing with the SEC today disclosed a substantial insider sale of Avexis shares as — Dr Brian K Kaspar, Director and Officer — disposed of 15,000 shares in the company having a market value of approximately $1,892,187. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the sale of 45,000 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 60,000 shares and have averaged 30,000 shares per transaction over this time period.

The number of insider buy/sell trades at Avexis is greater than that of the 285 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 324 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares traded per transaction by Avexis insiders is lower than its peers. Within the peer group there were 27,547,215 shares purchased and 14,419,372 shares sold with company insiders having bought 63,727 shares on average over this time period.

In order to focus on significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated data sourced to compose and write this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.